NPCE · Neuropace Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.07M | - | $27.35M | $23.52M | $22.52M | - | $21.06M | $19.26M | $18.12M | - |
| Cost of Revenue | $4.02M | - | $6.19M | $5.39M | $5.18M | - | $5.64M | $5.12M | $4.78M | - |
| Gross Profit | $18.05M | - | $21.17M | $18.13M | $17.34M | - | $15.42M | $14.13M | $13.34M | - |
| R&D | $7.19M | - | $6.58M | $6.84M | $7.44M | - | $5.75M | $6.07M | $5.78M | - |
| SG&A | $4.05M | - | $4.59M | $6.07M | $15.05M | - | $13.91M | $14.30M | $15.10M | - |
| Total Operating Expenses | $23.62M | - | $23.77M | $24.96M | $22.49M | - | $19.66M | $20.36M | $20.89M | - |
| D&A | $60.0K | - | $100.0K | $100.0K | $49.0K | - | $100.0K | $100.0K | $45.0K | - |
| Operating Income | ($5.57M) | - | ($2.60M) | ($6.82M) | ($5.15M) | - | ($4.24M) | ($6.23M) | ($7.54M) | - |
| Interest Expense | $1.52M | - | $1.65M | $2.06M | $2.26M | - | $2.18M | $2.13M | $2.26M | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($6.69M) | - | ($3.50M) | ($8.65M) | ($6.59M) | - | ($5.45M) | ($7.51M) | ($8.93M) | - |
| EPS - Basic | ($0.20) | - | ($0.11) | ($0.26) | ($0.21) | - | ($0.19) | ($0.26) | ($0.32) | - |
| EPS - Diluted | ($0.20) | - | ($0.11) | ($0.26) | ($0.21) | - | ($0.19) | ($0.26) | ($0.32) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.78M | $21.69M | $20.65M | $22.86M | $27.02M | $13.43M | $15.42M | $12.84M | $13.00M | $18.06M |
| Accounts Receivable | $14.79M | $14.68M | $14.94M | $13.55M | $15.44M | $12.85M | $11.56M | $11.24M | $11.63M | $12.31M |
| Inventory | $16.69M | $16.90M | $18.14M | $16.35M | $13.58M | $13.38M | $12.08M | $11.36M | $11.42M | $11.21M |
| Accounts Payable | $4.51M | $2.22M | $4.59M | $4.72M | $4.05M | $2.95M | $2.16M | $2.29M | $3.27M | $2.33M |
| Current Assets | $86.98M | $94.07M | $95.33M | $93.74M | $97.48M | $81.34M | $82.59M | $80.23M | $84.25M | $92.72M |
| Total Assets | $98.90M | $105.56M | $107.25M | $106.11M | $110.20M | $94.65M | $96.30M | $94.39M | $98.85M | $107.65M |
| Current Liabilities | $16.17M | $17.81M | $19.61M | $17.14M | $14.71M | $15.16M | $14.78M | $12.59M | $13.11M | $16.23M |
| Long-term Debt | $59.02M | $58.88M | $58.75M | $58.62M | $59.79M | $59.52M | $59.27M | $59.02M | $58.04M | $56.95M |
| Total Liabilities | $84.44M | $86.53M | $88.74M | $86.68M | $85.94M | $86.63M | $86.48M | $84.50M | $84.51M | $87.00M |
| Stockholders' Equity | $14.45M | $19.03M | $18.52M | $19.44M | $24.27M | $8.01M | $9.82M | $9.88M | $14.34M | $20.65M |
| Retained Earnings | ($559.10M) | ($552.41M) | ($549.69M) | ($546.19M) | ($537.54M) | ($530.95M) | ($525.70M) | ($520.25M) | ($512.73M) | ($503.81M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.90M) | - | - | - | ($7.48M) | - | - | - | ($7.53M) | - |
| Investing Cash Flow | ($117.0K) | - | - | - | ($37.0K) | - | - | - | $2.40M | - |
| Financing Cash Flow | ($166.0K) | - | - | - | $21.11M | - | - | - | $72.0K | - |
| CapEx | $117.0K | - | - | - | $37.0K | - | - | - | $104.0K | - |
| Free Cash Flow | ($6.02M) | - | - | - | ($7.52M) | - | - | - | ($7.63M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 81.8% | - | 77.4% | 77.1% | 77.0% | - | 73.2% | 73.4% | 73.6% | - |
| Operating margin | -25.2% | - | -9.5% | -29.0% | -22.9% | - | -20.1% | -32.4% | -41.6% | - |
| EBITDA margin | -25.0% | - | -9.1% | -28.6% | -22.6% | - | -19.7% | -31.8% | -41.4% | - |
| Net margin | -30.3% | - | -12.8% | -36.8% | -29.3% | - | -25.9% | -39.0% | -49.2% | - |
| Free cash flow margin | -27.3% | - | - | - | -33.4% | - | - | - | -42.1% | - |
| FCF / Net income | 0.90 | - | - | - | 1.14 | - | - | - | 0.86 | - |
| R&D / Revenue | 32.6% | - | 24.0% | 29.1% | 33.0% | - | 27.3% | 31.5% | 31.9% | - |
| SG&A / Revenue | 18.3% | - | 16.8% | 25.8% | 66.8% | - | 66.0% | 74.3% | 83.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.8% | - | -3.3% | -8.2% | -6.0% | - | -5.7% | -8.0% | -9.0% | - |
| Return on equity | -46.3% | - | -18.9% | -44.5% | -27.1% | - | -55.5% | -76.0% | -62.2% | - |
| Return on invested capital | -6.0% | - | -2.7% | -6.9% | -4.8% | - | -4.9% | -7.1% | -8.2% | - |
| Liquidity | ||||||||||
| Current ratio | 5.38 | 5.28 | 4.86 | 5.47 | 6.63 | 5.37 | 5.59 | 6.37 | 6.43 | 5.71 |
| Quick ratio | 4.35 | 4.33 | 3.94 | 4.51 | 5.70 | 4.48 | 4.77 | 5.47 | 5.56 | 5.02 |
| Cash ratio | 0.91 | 1.22 | 1.05 | 1.33 | 1.84 | 0.89 | 1.04 | 1.02 | 0.99 | 1.11 |
| Leverage | ||||||||||
| Debt / Equity | 4.08 | 3.09 | 3.17 | 3.02 | 2.46 | 7.43 | 6.03 | 5.97 | 4.05 | 2.76 |
| Debt / Assets | 0.60 | 0.56 | 0.55 | 0.55 | 0.54 | 0.63 | 0.62 | 0.63 | 0.59 | 0.53 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -3.7x | - | -1.6x | -3.3x | -2.3x | - | -1.9x | -2.9x | -3.3x | - |
| Equity multiplier | 6.84 | 5.55 | 5.79 | 5.46 | 4.54 | 11.81 | 9.80 | 9.55 | 6.89 | 5.21 |
| Liabilities / Assets | 0.85 | 0.82 | 0.83 | 0.82 | 0.78 | 0.92 | 0.90 | 0.90 | 0.85 | 0.81 |
| Efficiency | ||||||||||
| Asset turnover | 0.22 | - | 0.26 | 0.22 | 0.20 | - | 0.22 | 0.20 | 0.18 | - |
| Inventory turnover | 0.24 | - | 0.34 | 0.33 | 0.38 | - | 0.47 | 0.45 | 0.42 | - |
| Days sales outstanding | 245d | - | 199d | 210d | 250d | - | 200d | 213d | 234d | - |
| Days inventory outstanding | 1516d | - | 1070d | 1107d | 957d | - | 782d | 810d | 872d | - |
| Days payable outstanding | 410d | - | 271d | 320d | 285d | - | 140d | 163d | 249d | - |
| Cash conversion cycle | 1351d | - | 999d | 998d | 922d | - | 843d | 860d | 856d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 30.7x | - | 18.4x | 18.8x | 15.9x | - | 20.9x | 22.1x | 26.0x | - |
| P / S | 20.1x | - | 12.5x | 15.6x | 17.2x | - | 9.7x | 11.3x | 20.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -2.0% | - | 29.9% | 22.1% | 24.3% | - | 28.2% | 16.6% | 25.2% | - |
| Revenue CAGR (3y) | 15.1% | - | 34.8% | 32.1% | 25.6% | - | 18.1% | 15.1% | 22.0% | - |
| Revenue CAGR (5y) | 17.2% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 4.1% | - | 37.3% | 28.3% | 30.0% | - | 26.1% | 18.1% | 28.6% | - |
| Operating income growth (YoY) | -8.2% | - | 38.7% | -9.5% | 31.8% | - | 28.7% | 20.7% | 9.3% | - |
| Net income growth (YoY) | -1.5% | - | 35.9% | -15.1% | 26.2% | - | 24.9% | 17.6% | 14.0% | - |
| EPS growth (YoY) | 4.8% | - | 42.1% | 0.0% | 34.4% | - | 32.1% | 27.8% | 22.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 20.0% | - | - | - | 1.5% | - | - | - | 22.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -40.4% | 137.5% | 88.5% | 96.6% | 69.2% | -61.2% | -40.0% | -53.4% | -47.8% | -40.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$900.0K totalNon Us$900.0K · 100.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing NeuroPace Inc against the 5 most active filers in the same SIC group.